Skip to main content

Roche and Novartis among most valuable companies

| News

Roche and Novartis among most valuable companies


The Basel pharmaceutical companies Roche and Novartis are among the 40 most valuable companies in the world, according to an EY study. American tech firms top the list.

Money. (Img: aleksandra85foto/pixabay)

The consultancy firm EY has again compared the 300 highest rated companies in the world – and once again the top 100 is dominated by US companies. Three Swiss companies were among the top 100: Nestlé ($264 billion/18th place), Roche ($213 billion/31st place) and Novartis ($195 billion/37th place).

“Although the European economy is now recovering sharply, Europe’s top companies still continue to play only a minor role on the world’s stock exchanges,” said Stefan Rösch, partner and head of transaction services at EY in Switzerland. “Although we are still well ahead with Nestlé and our two pharma companies, the opportunities offered by digitalization nonetheless need to be exploited more effectively in this country.”

Three US companies from the tech sector – Apple ($876 billion), Google’s owner Alphabet ($733 billion) and Microsoft ($661 billion) – captured the top three places. The Chinese internet giants Tencent and Alibaba, which doubled in value over the past year, also made it into the top 10. The US company Johnson & Johnson ($377 billion) was the highest ranked pharmaceutical company, coming in 10th place.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.